Feedback / Questions
FYB201 (ranibizumab biosimilar) - Amneal, Formycon, Coherus Biosci, Teva
https://www.dgap.de/dgap/News/corporate/ms-pharma-wird-kommerzialisierungspartner-fuer-fyb-formycons-biosimilarkandidat-fuer-lucentisr-ranibizumab-der-menaregion/?newsID=1494063
Dec 14, 2021
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next